Cargando…
Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer
Androgen deprivation therapy (ADT) and androgen receptor (AR)-targeted therapy are the gold standard options for treating prostate cancer (PCa). These are initially effective, as localized and the early stage of metastatic disease are androgen- and castration-sensitive. The tumor strongly relies on...
Autores principales: | Pungsrinont, Thanakorn, Kallenbach, Julia, Baniahmad, Aria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538152/ https://www.ncbi.nlm.nih.gov/pubmed/34681745 http://dx.doi.org/10.3390/ijms222011088 |
Ejemplares similares
-
Androgen receptor agonist and antagonist reduce response of cytokine‐induced killer cells on prostate cancer cells
por: Pungsrinont, Thanakorn, et al.
Publicado: (2023) -
Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer
por: Kokal, Miriam, et al.
Publicado: (2020) -
PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011) -
A Novel Splice Variant of the Inhibitor of Growth 3 Lacks the Plant Homeodomain and Regulates Epithelial–Mesenchymal Transition in Prostate Cancer Cells
por: Melekhova, Anna, et al.
Publicado: (2021) -
Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells
por: Gupta, Siddharth, et al.
Publicado: (2020)